FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

| Check this box if no longer subject |
|-------------------------------------|
| to Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* MOORE ALISON | | | | | | 2. Issuer Name and Ticker or Trading Symbol Allogene Therapeutics, Inc. [ALLO] | | | | | | | | | all app | o of Reportir licable) tor er (give title | ng Pei | rson(s) to Is 10% O Other (| wner |
|---|---|-------|----------------------------|----------------------------|---|--|----------------------------------|------------------|------|--|--|---------------|--|--|------------------------|--|--|---|----------|
| (Last) (First) (Middle) 210 EAST GRAND AVENUE | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/15/2021 | | | | | | | | | below) Chief Techn | | nical | below) | |
| 1 | Street) SOUTH SAN FRANCISCO CA 94080 | | | 4. If a | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | on | |
| (City) | (Sta | | Zip) | | | | | | | | | | | | | | | | |
| | | Table | I - I | Non-Deriva | tive | Secui | rities | Ac | quir | ed, Di | isposed c | f, or I | Benefic | ially | Own | ed | | | |
| 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea | | | | ear) E | 2A. Deemed Execution Da if any (Month/Day/Y | | Date, | | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar | | | nd 5) Secui Benet | | icially d Following | Forr (D) o Indii | n: Direct or rect (I) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | | - | Code | v . | Amount | (A) or (D) | Price | Trans | | action(s) 3 and 4) | (III) | 3u. 4) | (1130.4) |
| Common Stock 03/15/2021 | | | | | 1 | | | S ⁽¹⁾ | | 6,164 | D | \$38.13 | 91 ⁽²⁾ | 102,574 ⁽³⁾ | | | D | | |
| | | Tal | ble | II - Derivati (e.g., pu | | | | | | | posed of, converti | | | |)wne | d | | | |
| 1. Title of Derivative Security (Instr. 3) | Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) | | 4. Transa Code 8) | | nstr. Derivative Securitie: Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | Expiration Date (Month/Day/Year) | | | Amo Secu Unde Deriv Secu 3 and | 7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4) Amoun or Numbe of Title Shares | | rice of ivative urity tr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |

Explanation of Responses:

- 1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$37.96 to \$38.395, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- 3. Includes 368 shares of the Issuer's common stock acquired by the reporting person on March 15, 2021 pursuant to an employee stock purchase program.

Remarks:

/s/ Veer Bhavnagri, Attorneyin-Fact

03/17/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.